AzTrials
AzTrials

Kidney DiseasesCLARIFy-KDNCT06693661

Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease

A study testing Kidney Health Coaching in people with Kidney Diseases, run by Emory University at 2 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Through the use of community-engaged processes, this project seeks to develop and implement clinical decision support (CDS) and a kidney health coaching (KHC) intervention. The CDS seeks to streamline workflows to effectively screen, identify, and link to care for those patients with advanced chronic kidney disease… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Kidney Diseases
What is being tested?
Kidney Health Coaching
Could I receive a placebo?
No, everyone receives an active treatment
How many people
600 participants
Where
2 sitesUnited States
Study dates
10 Mar 2026to Mar 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Identifies as African American or Black
  • Two estimated glomerular filtration rates (eGFRs) < 29 separated by at least 90 days but within the past 2 years, or a Kidney Failure Risk Equation (KFRE) score of 10% or greater likelihood of kidney failure within the next 2 years
  • Had an encounter at Emory Healthcare through an ambulatory visit or inpatient stay (i.e., ER or hospital visit within the previous 2 months
  • Stated willingness to comply with all study procedures and availability for the duration of the study

Who cannot join

  • Currently on dialysis
  • currently receiving hospice care or other types of conservative management for terminal illness
  • Currently on waitlist, or referred for/or completed a transplant evaluation visit within the past 2 years
  • Kidney or another solid organ transplant
  • Active cancer treatment
  • Non-English speaking
  • Participating in another treatment or intervention study at the time of enrollment
  • Currently pregnant or planning to become pregnant at the time of recruitment

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Kimberly R Jacob Arriola, PhD, MPH contact

404-727-2600

kjacoba@emory.edu

United States2 sites, 2 recruiting
  • Emory University Hospital Midtown

    Atlanta, Georgia, 30308

    Recruiting
  • Emory Healthcare System

    Atlanta, Georgia, 30322

    Recruiting

Other trials in United States

About this study

Official title: Improving Access to Nephrology Treatment and Care Among Patients at Greatest Risk for Kidney Failure

Through the use of community-engaged processes, this project seeks to develop and implement clinical decision support (CDS) and a kidney health coaching (KHC) intervention. The CDS seeks to streamline workflows to effectively screen, identify, and link to care for those patients with advanced chronic kidney disease (CKD).

The overall project goals are to 1.) Design and conduct community-engaged clinical trials to test new interventions that dismantle the systemic factors that contribute to kidney health disparities. 2.) Foster research collaborations between investigators, people living with kidney disease, community-based organizations, and other key stakeholders.

Researchers aim to assess whether the KHC intervention is effective at delaying the transition to kidney replacement therapy (KRT) and central venous catheter use or death.

Read the detailed description

The team aims to implement multi-level, multi-component interventions across primary care and acute care access points and nephrology care, using an experimental 2-group randomized controlled trial, to assess the effectiveness of a kidney health coaching intervention on delaying a) the transition to kidney replacement therapy and central venous catheter use and b) death.

The research team will deliver patient-centered kidney health coaching through full-time kidney health coaches (KHCs), who have lived experience with chronic kidney disease (CKD) and have been selected for certain personality characteristics. The KHCs have undergone training to deliver patient support that aligns with the constructs of the Chronic Care Model: Clinical information systems, Patient self-management, and treatment decision-making support, Delivery system redesign, and Community resources.

Participants enrolled in the intervention will receive 6 months of kidney health coaching. Those eligible for participation will be invited to participate and undergo the informed consent process via telephone. Next, study staff will administer the baseline assessment via telephone interview for those who consent.

Conditions
Kidney Diseases
Being tested
Kidney Health Coaching, Usual Care
Keywords
African American, Health Disparities, Chronic Care Model (CCM), Kidney Health Coach (KHC)
Medical subject headings
Kidney Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Kidney Health CoachingOther

    Also called KHC Protocol

    The intervention entails support from a KHC that includes:

    • An initial rapport-building call
    • Ongoing telephone support at least twice a month for six months
    • Meeting the patient at all in-person clinic appointments
    • Documenting interactions in the EMR using a customized platform

    Telephone support begins with a social determinants of health (SDoH) screening tool to identify barriers and facilitators to CKD self-management and appointment adherence. This tool provides access to local resources based on the patient's ZIP code. Subsequent calls will follow up on resource usage, review CKD educational materials and treatment options, complete the Decision Aid for Renal Therapy tool, and facilitate communication through the patient portal. Each call will start with specific goals (e.g., review National Kidney Foundation CKD materials) and conclude with goals for the next session.

  • Usual CareOther

    Also called Control

    ER Discharge (d/c): Participants may receive consultations and support from Care Management in the ER, such as transportation or medication assistance. Follow-up by a social worker varies post-discharge.

    Hospital d/c: All hospitalized patients are assessed by the care management team to identify psychosocial needs and begin discharge planning, which may include follow-up appointments and resources. High-risk patients receive additional follow-up from a care transitions coordinator for 30 days post-discharge.

    Primary Care: Patients in primary care clinics have access to various support services. Those recently hospitalized or identified as high-risk receive care coordination from social workers. Internal referrals are managed by referral coordinators, while external referrals come from clinic staff. Discharge information is provided after visits.

    Nephrology: There are no coordinated support services for chronic kidney disease (CKD) patients receiving nephrology care.

Study groups in NCT06693661
Study groupRoleWhat they receive
Intervention: Kidney Health CoachingOtherParticipants will receive patient-centered health coaching delivered by three full-time kidney health coaches for six months.
Receives: Other: Kidney Health Coaching
Control: Usual CareOtherParticipants will receive the usual care based on where patients are identified (Emergency Room- ER, Primary Care, Hospital Discharge, Primary Care, or Nephrology)
Receives: Other: Usual Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time-to-Kidney Replacement Therapy w/Central Venous Catheter

    Composite measure of time to transition to Kidney Replacement Therapy (KRT) using a central venous catheter (CVC) over the course of the study period

    Measured: Throughout study participation up to 12 months

  2. Time-to-death

    Composite measure of time to death over the course of the study period. A record of death in the electronic medical record (EMR), and the date of death will be recorded. If the data is not available in EMR, national death statistics will be checked, and the patient's family will be asked.

    Measured: Throughout study participation up to 12 months

Secondary outcomes (18)
  1. Time to progression to end stage kidney disease (ESKD)

    Composite measure of time to ESKD diagnosis over the course of the study period. Progression to ESKD will be analyzed using monthly data collected from the EMR, capturing each participant's progression characterized by a significant loss of kidney function (defined as a glomerular filtration rate (GFR) of less than 15 mL/min) requiring KRT. Time to event will be calculated for all participants at the end of the follow-up period.

    Measured: Throughout study participation up to 12 months

  2. Time-to-optimal Kidney Replacement Therapy (KRT) referral

    Composite measure of time to referral for optimal KRT start over the course of the study. This includes referral for vascular surgery, preemptive kidney transplant evaluation, and/or home dialysis initiation. Data will be collected monthly from the EMR.

    Measured: Throughout study participation up to 12 months

  3. Number of participants who transition-to-Kidney Replacement Therapy w/Central Venous Catheter

    Number of participants who transitioned to Kidney Replacement Therapy (KRT) with the use of a central venous catheter (CVC) during the course of the study.

    Measured: Throughout study participation up to 12 months

  4. Mortality rate

    Mortality during study participation.

    Measured: Throughout study participation up to 12 months

  5. Nephrology appointment attendance

    Continuous measure of nephrology appointment adherence measured as the ratio of # appointments attended to # appointments scheduled during the course of the study. At the end of the follow-up period for all participants, the researchers will calculate the proportion of appointments attended as a measure of appointment adherence. This will be captured from the Emory Healthcare appointment-keeping system.

    Measured: Throughout study participation up to 12 months

  6. CKD Symptom Burden

    Self-reported occurrence of physical and emotional symptoms commonly experienced in individuals with CKD. Participants will complete a 29-item CKD Symptom Burden questionnaire that captures the frequency at which patients experience symptoms. Response options are on a 4-point scale (0 'never' to 4 'every day'). The summed total score ranges from 0 to 29. The greater the frequency of symptoms, the poorer the health-related and self-perceived quality of life.

    Measured: Baseline, 6 months and 12 months

  7. Quality of Life Scale

    Participants will complete a 10-item phone survey that assesses their perceived quality of life. Responses are recorded on a 5-point scale, with total scores ranging from 10 to 50; higher scores indicate better self-reported health-related quality of life.

    Measured: Baseline, 6 months and 12 months

  8. Patient activation Score

    Patient activation will be measured using the Patient Activation Measure (PAM), completed by phone. PAM is a validated self-reported questionnaire designed to assess an individual's knowledge, skills, and confidence in managing their well-being. It captures participants' agreement with 22 statements regarding their self-efficacy in maintaining health, measured on a scale from "Strongly Disagree" to "Strongly Agree." The response options are on a 4-point scale. Scores range from 0 to 100, with higher scores indicating greater activation.

    Measured: Baseline, 6 months and 12 months

  9. Decisional conflict scale

    Decisional conflict will be measured using the Decisional Conflict Scale (DCS). The DCS measures personal perceptions of uncertainty in choosing options. The survey will be conducted over the phone to capture the level of agreement a participant has with 16 statements regarding their ability to make an informed decision, measured on a scale from "Strongly Disagree" to "Strongly Agree." The response options are on a 5-point scale. Scores can range from 16 to 70. Higher Scores indicate higher decisional conflicts.

    Measured: Baseline, 6 months and 12 months

  10. Medical Mistrust Organization Score

    Medical mistrust organization will be measured using the Medical Mistrust Index adapted to address general mistrust of healthcare providers. Participants will answer the questions over the phone. Questions will capture their level of agreement with seven statements regarding healthcare organizations. Responses are measured on a 4-point scale, ranging from "Strongly Disagree" to "Strongly Agree". Scores can range from 7 to 28.

    Measured: Baseline, 6 months and 12 months

  11. Discrimination in Medical Settings (DMS) Scale

    DMS Scale is a validated, 7-item, 5-point Likert survey (1=never, 5=almost always) adapted from the Everyday Discrimination Scale to measure patients' self-reported experiences of, or perceptions of, mistreatment by healthcare providers due to factors like race, sex, or age. It assesses, for instance, if a patient is treated with less courtesy, respect, or receives poorer service, ranging from 7 to 35. There is no single "official" cutoff score that defines the presence of discrimination for everyone, as the DMS Scale is designed to measure the frequency of experiences on a continuous spectrum, with higher scores indicating more frequent experiences of discrimination.

    Measured: Baseline, 6 months and 12 months

  12. CKD treatment Knowledge

    To measure participants' CKD treatment knowledge, they will complete a 9-item yes/no questionnaire over the phone. The research team will count the number of correct responses, resulting in a score ranging from 0 to 9.

    Measured: Baseline, 6 months and 12 months

  13. Rotterdam Renal Replacement Knowledge test

    KRT knowledge will be measured using the Rotterdam Renal Replacement Knowledge test. Participants will complete the 21-item test over the phone, assessing their understanding of renal replacement therapy. The research team will count the correct responses, allowing scores to range from 0 to 21. Higher scores suggest a better understanding of KRT, indicating preparedness to make informed decisions about treatment options.

    Measured: Baseline, 6 months and 12 months

  14. Shared Decision-Making Score

    Shared decision-making will be measured using the Shared Decision-Making Q-9. Participants will respond by phone to 16 statements regarding their ability to make informed decisions, using a 5-point scale from "Strongly Disagree" to "Strongly Agree." Scores will range from 16 to 80.

    Interpretation of Scores:

    Low Score (16-40): Indicates poor shared decision-making, suggesting the patient may feel uninformed or not involved in their care.

    Moderate Score (41-60): Reflects a moderate level of shared decision-making, indicating some collaboration occurs but that improvements are needed.

    High Score (61-80): Suggests strong shared decision-making, where patients feel well-informed and actively involved in their healthcare decisions.

    Measured: Baseline, 6 months and 12 months

  15. Brief Health Literacy Screening Tool (BRIEF)

    The BRIEF tool is a four-question screening test where clinicians can ask patients four questions to determine their health literacy level (the degree to which one can read, understand, exchange, and use health information and resources). Each item is worth 1 to 5 points depending on the response (1=Always, 5=Never). The values for the four responses are added for a total score, which ranges from a minimum of 4 to a maximum of 20.

    Interpretation of Scores:

    Limited (4 -12): Not able to read most low-literacy health materials; will need repeated oral instructions; materials should have illustrations or videotapes. Will need low literacy materials; may not be able to read a prescription label.) Marginal (13 - 16): Will be able to read and comprehend most patient education materials.

    Adequate (17 - 20): Will be able to read and comprehend most patient education materials.

    Measured: Baseline, 6 months and 12 months

  16. Participants with Health-Related Social Needs

    Health-Related Social Needs (HRSN) Identified via the Accountable Health Communities Health-Related Social Needs (AHC HRSN) Screening Tool. HRSNs will be identified using the AHC HRSN Screening Tool, which includes five core domains (housing instability, food insecurity, transportation problems, utility help needs, interpersonal safety). Outcomes reflect the number of participants with one or more HRSNs.

    Measured: Baseline, 6 months and 12 months

  17. Patient Health Questionnaire (PHQ-9)

    The Patient Health Questionnaire-9 (PHQ-9) is a self-administered 9-item tool used to screen, diagnose, and monitor the severity of depression in adults. It assesses symptoms over the past two weeks based on the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria, with scores ranging from 0 to 27. A score of >=10 typically indicates moderate depression, requiring further clinical evaluation.

    Interpretation of Scores:

    0-4: Minimal or no depression (monitor) 5-9: Mild depression (use clinical judgment) 10-14: Moderate depression (active treatment) 15-19: Moderately severe depression 20-27: Severe depression

    Measured: Baseline, 6 months and 12 months

  18. General Anxiety Disorder (GAD-7)

    The Generalized Anxiety Disorder scale-7 (GAD-7) is a seven-item diagnostic tool validated in both the primary care setting and the general population, with reporting scores from 0 to 3 on all questions. It investigates how often the patient has been bothered by seven different symptoms of anxiety during the last two weeks, with response options such as " not at all," " several days '," more than half the days," and " nearly daily " scored as 0, 1, 2, and 3, respectively. The scores of 5, 10, and 15 are taken as cut-off points for mild, moderate, and severe anxiety, respectively.

    Interpretation of Scores:

    0-4: minimal anxiety 5-9: mild anxiety 10-14: moderate anxiety 15-21: severe anxiety

    Measured: Baseline, 6 months and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2024
  2. Study start10 Mar 2026
  3. Primary completionMar 2028 (estimated)
  4. Study completionMar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Care provider, Investigator, Outcomes assessor
Enrolment
600 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06693661
Sponsor's protocol ID
STUDY00007938
Other IDs
1U01DK137269, 2025P008750
Acronym
CLARIFy-KD
Status last verified
Jun 2026
First submitted
14 Nov 2024
Last updated
4 Jun 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The investigator will share individual de-identified data that supports statistical analysis

Questions about this trial

What is this clinical trial studying?

A study testing Kidney Health Coaching in people with Kidney Diseases, run by Emory University at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Kimberly R Jacob Arriola, PhD, MPH (404-727-2600, kjacoba@emory.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time-to-Kidney Replacement Therapy w/Central Venous Catheter (time frame: Throughout study participation up to 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in